Criteria to qualify for study: Drug used in study:
  • Newly diagnosed AL amyloidosis. Diagnosis will be based on histopathological or electron microscopy criteria, one or more organs need to be affected, and disease must be measured by free light chain criteria. Eligible subjects will have an ECOG performance score of 0, 1, or 2 and adequate organ function.

AMY 05 54767414AMY3001

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) compared with CyBorD alone in newly diagnosed Systemic AL Amylodosis.